{"id":32096,"date":"2026-07-07T21:35:00","date_gmt":"2026-07-07T19:35:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=cf9c94232f4723181acf38491cc360c9"},"modified":"2026-07-07T21:35:00","modified_gmt":"2026-07-07T19:35:00","slug":"spear-bio-to-unveil-novel-alzheimers-disease-immunoassays-and-fully-automated-instrument-platform-at-aaic-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=32096","title":{"rendered":"Spear Bio to Unveil Novel Alzheimer\u2019s Disease Immunoassays and Fully Automated Instrument Platform at AAIC 2026"},"content":{"rendered":"

\nLaunches include the first commercially available singleplex eMTBR-Tau immunoassay, a novel pTau 217 assay for venous and capillary blood, and a fully automated instrument platform<\/i><\/p><\/a><\/a>

WOBURN, Mass.--(BUSINESS WIRE)--Spear Bio, an innovator in ultrasensitive protein biomarker detection, today announced plans to unveil new SPEAR immunoassay and instrument innovations at the Alzheimer\u2019s Association International Conference\u00ae<\/sup> 2026, taking place July 12\u201315 in London, UK.<\/p>

\nThe launches include the first commercially available singleplex immunoassay for eMTBR-Tau, a novel epTau 217 assay for measuring pTau 217 across venous and capillary blood, and an instrument platform to fully automate SPEAR workflows. Together, these innovations expand Spear Bio\u2019s Alzheimer\u2019s disease and neurodegenerative biomarker portfolio, giving scientists new tools to investigate both amyloid-associated tau phosphorylation and tau tangle pathology from ultra-low sample volumes.<\/p>

\nDesigned as a standalone singleplex assay, the SPEAR eMTBR-Tau immunoassay provides researchers a focused and quantitative approach to measuring tau tangle-associated biology while maintaining the ultra-low sample volume and simplified workflow advantages of SPEAR technology. SPEAR epTau 217 complements this approach by enabling consistent pTau 217 measurement across venous and capillary blood, supporting broader investigation of amyloid-associated tau phosphorylation in Alzheimer\u2019s disease research.<\/p>

\nBoth assays are built on Spear Bio\u2019s proprietary Successive Proximity Extension Amplification Reaction technology, which combines attomolar sensitivity with a homogeneous, wash-free workflow. Requiring just 1 \u00b5L of diluted plasma, SPEAR immunoassays help researchers preserve precious biospecimens while generating high-quality biomarker data across Alzheimer\u2019s disease, neurodegeneration, and preclinical research.<\/p>

\nThe new instrument platform is designed to fully automate SPEAR workflows from sample to qPCR-ready plate, reducing manual handling and supporting more consistent execution of ultrasensitive biomarker assays. The system represents an important step in making SPEAR technology easier to adopt, scale, and integrate into research and clinical development laboratory workflows.<\/p>

\n\u201cOur focus is on building innovations that help researchers answer questions that were previously difficult to address with conventional protein biomarker tools,\u201d said Feng Xuan, Founder and Chief Executive Officer of Spear Bio. \u201cAs the field advances from biomarker discovery toward broader validation, vigorously verified assays become essential to generating reliable, reproducible insights. By bringing together novel biomarker content, enabled by SPEAR\u2019s ultra-sensitivity and performance required for biomarker validation, we are providing researchers with a platform to measure complex Alzheimer\u2019s disease biology and support the next stage of neurodegenerative disease research.\u201d<\/p>

\nSpear Bio at AAIC 2026<\/span><\/b><\/p>

\nSpear Bio will exhibit at booth 322 and present new data across Alzheimer\u2019s disease, neurodegeneration, synucleinopathy, and TDP-43 proteinopathy.<\/p>

\nProduct Theater Presentation<\/b><\/p>